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Abstract The luteinizing hormone/choriogonadotropin hormone
receptor (LH/CG R) signals to regulate ovulation, corpus luteum
formation, and fetal survival during pregnancy. Agonist binding
to the LH/CG R is poorly reversible, emphasizing the importance
of a cellular mechanism to temper signaling by a potentially
persistently active receptor. Like other G protein-coupled
receptors (GPCRs), signaling by this receptor is modulated by
its binding of an arrestin. We have identified ADP ribosylation
factor 6 (ARF6) as a protein whose activation state is regulated
by the LH/CG R and which functions to regulate the availability
of plasma membrane-docked arrestin 2 to this receptor. We
hypothesize that ARF6 might also serve GPCRs other than the
LH/CG R to regulate the availability of arrestin 2 for receptor
desensitization. + 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
Key words: ADP ribosylation factor 6; ADP ribosylation
factor nucleotide binding site opener; Arrestin;
G protein-coupled receptor
1. Introduction
ADP ribosylation factor 6 (ARF6) is an abundant plasma
membrane-localized protein [1] poised to modulate signaling
of the large family of guanine nucleotide-binding (G) protein-
coupled receptors (GPCRs). ARF6 is a monomeric G protein
which cycles between a GDP-bound inactive conformation
and a GTP-bound active conformation [2]. Rate-limiting
GDP release is catalyzed by a class of guanine nucleotide
exchange factors (GEFs), which include the ARF nucleotide
binding site opener (ARNO)/cytohesin, exchange factor for
ARF6 (EFA6), and ARF-guanine nucleotide exchange pro-
tein 100 (ARF-GEP100) subclasses [3,4]. The GTPase activity
of ARF6 [2] is stimulated by a family of GTPase activating
proteins (GAPs) [5^7]. Functions attributed to ARF6 include
regulation of membrane ru¥ing and cell motility, aspects of
endocytosis, exocytosis, and membrane recycling, as well as
reorganization of the cortical actin cytoskeleton and activa-
tion of phospholipase D [6,8,9]. Although it has been recog-
nized for some time that activation of an ARF occurs upon
agonist activation of a number of di¡erent GPCRs, including
the L2-adrenergic, m3 muscarinic acetylcholine, fMet-Leu-
Phe, H1 histamine, gonadotropin releasing hormone, and B2
bradykinin receptors [10^13], the function of this ARF is
poorly understood. We showed that an ARF is also activated
following agonist binding to the luteinizing hormone/chorio-
gonadotropin hormone receptor (LH/CG R) [14], and identi-
¢ed that ARF as ARF6 [15].
We recently described an unappreciated role for the activa-
tion of ARF6 in desensitization of the LH/CG R. We have
established that the activation state of ARF6 in ovarian fol-
licular membranes regulates the availability to the LH/CG R
of a pool of arrestin 2, as summed in the model presented in
Fig. 1. In the inactive ARF6GDP conformation, arrestin 2 is
bound to ARF6 (directly or indirectly) and is not accessible to
the receptor (Fig. 1A). With ARF6 activation, arrestin 2 is
undocked from ARF6 (Fig. 1B) and now available to bind to
active LH/CG R to promote desensitization (Fig. 1C). Recent
evidence shows that desensitization of the LH/CG R hetero-
logously expressed in human embryonic kidney 293
(HEK293) cells also requires ARF6 activation [16]. This result
supports the hypothesis that the availability of arrestin 2 for
desensitization of GPCRs other than the LH/CG R might also
be regulated by the activation state of ARF6. Data which led
to identi¢cation of a role for ARF6 in regulating the avail-
ability of arrestin 2 to the LH/CG R are reviewed in this
report.
2. GPCR desensitization and internalization
GPCR desensitization describes the uncoupling of a GPCR from its
cognate G protein and results in reduced signaling of the receptor to
the G protein-linked e¡ector. Based initially on rhodopsin [17,18] and
subsequently on L2-adrenergic receptor (L2-AR) [19,20], desensitiza-
tion of GPCRs is generally believed to be triggered by the recruitment
of and consequent phosphorylation of the GPCR by a G protein-
regulated kinase (GRK). An arrestin is then recruited from the cytosol
[21] and upon interacting with the phospho-receptor, binds to receptor
with high a⁄nity [22]. The mammalian arrestins include the visual
arrestins (arrestin 1 and arrestin 4) and the ubiquitous arrestin 2 (or
Larrestin 1) and arrestin 3 (or Larrestin 2) [23]. Arrestin mediates
receptor desensitization by sterically hindering the ability of the re-
ceptor to activate its cognate G protein [24]. For receptors other than
rhodopsin, arrestin also serves as a sca¡old to target the receptor for
endocytosis, by binding clathrin and the L subunit of the clathrin
adapter protein AP-2 [25,26], and as a docking site for enzymes asso-
ciated with other signaling pathways, including those for the mitogen-
activated protein kinase/extracellular regulated kinases [19,27]. There-
fore, uncoupling of GPCRs from their associated G proteins can lead
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to the coupling of GPCRs to other signaling pathways. The majority
of results leading to these conclusions are based on the heterologous
expression of the GPCR, GRK, and the arrestin. Integrated into the
literature of receptor desensitization is an extensive literature on re-
ceptor internalization that is based on evidence that for many GPCRs,
receptor internalization results from GRK-dependent receptor phos-
phorylation and subsequent binding of an arrestin [20]. However, it is
not clear for most GPCRs outside the visual system whether the bind-
ing of arrestin to a particular site mediates both receptor desensitiza-
tion and internalization or whether there are two separate binding
sites possibly for distinct non-visual arrestins. Recent evidence for
the chemokine R CXCR4 [28], the L2-AR [29,30], and the LH/CG
R [16,31,32] suggests that desensitization and internalization of
GPCRs may be mediated by distinct pools of non-visual arrestins.
However, for a few receptors such as the LH/CG R, even though
this receptor exhibits GRK- and agonist-dependent phosphorylation
in a heterologous expression model leading to receptor desensitization
and internalization [33,34], receptor phosphorylation is not obligatory
for desensitization [35^39]. Moreover, LH/CG R desensitization in a
cell-free membrane model exhibits a critical requirement for GTP
[37,38,40,41]. Similar reports on the obligatory role of GTP in
GPCR desensitization exist for the endogenous L2-AR [42] and vaso-
pressin R [43] in kidney cell membranes. Desensitization of the LH/
CG R can also be reversed by the non-hydrolyzable GDP analog
GDPLS, generating an active receptor [44]. These results suggest ei-
ther that desensitization of the LH/CG R is mediated by a unique
mechanism or that the cell-free membrane model a¡orded identi¢ca-
tion of elements of desensitization not readily discernible in an intact
cellular model.
3. ARF6/arrestin 2-dependent LH/CG R desensitization
3.1. LH/CG R desensitization is mediated by membrane-
delimited arrestin 2
Desensitization of the native LH/CG R can be readily dem-
onstrated in a cell-free membrane model prepared from ovar-
ian follicles [45] (which endogenously express V10 000 recep-
tors/cell [46]). All of the proteins required to mediate
desensitization must therefore be present in this membrane
preparation. We initially determined whether uncoupling of
the LH/CG R from Gs and adenylyl cyclase (AC) was depen-
dent on the binding of a membrane-associated arrestin to the
receptor. The addition of neutralizing anti-arrestin antibodies
that block arrestin’s interaction with all GPCRs prevented
agonist from promoting desensitization [47]. Consistent with
this result, arrestin 2 but not arrestin 3 was readily detected by
Western blotting in an AC-enriched membrane preparation
Fig. 1. Model of LH/CG R desensitization. Shown in A is the docking of arrestin 2 at a membrane location distinct from the inactive LH/CG
R and in association with inactive ARF6GDP. Activation of the LH/CG R upon binding agonist, as shown in B, not only promotes activation
of the stimulatory heterotrimeric G protein Gs and consequent adenylyl cyclase (AC) activation by KsGTP, but also promotes activation of
ARF6 and liberation of arrestin 2. ARNO or a similar ARF6 GEF promotes GDP release from ARF6 in response to LH/CG R activation.
Arrestin 2 binding to the 3i loop of the active LH/CG R, shown in C, mediates desensitization by interfering with the ability of the agonist-ac-
tivated receptor to activate Gs.
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[47]. These results show that desensitization of the LH/CG R
requires a pool of membrane-delimited endogenous arrestin 2
and that this obligatory arrestin 2 need not be recruited from
another cellular compartment. However, arrestin 2 coimmu-
noprecipitated only with active but not with inactive native
receptor [16,48]. This result indicates that arrestin 2 must be
‘docked’ in the membrane at a site that is distinct from the
inactive LH/CG R (see Fig. 1A).
Arrestin 2 binds speci¢cally to the third intracellular (3i)
loop of the active LH/CG R. This conclusion is based on
evidence that a synthetic peptide corresponding to the 3i
loop of the receptor selectively competed with receptor for
arrestin 2 binding and blocked agonist-dependent receptor
desensitization [49]. Neither a scrambled 3i loop peptide nor
a 2i loop peptide blocked receptor desensitization [49]. More-
over, surface plasmon resonance studies showed that arrestin
2 bound with pM a⁄nity to the 3i loop peptide and exoge-
nous arrestin 2 promoted desensitization of the active intact
LH/CG R in follicular membranes with an ED50 ofV10 pM
[16]. Surprisingly, however, while visual arrestin 1 also bound
with pM a⁄nity to the 3i loop peptide of the LH/CG R and
promoted desensitization of intact receptor in follicular mem-
branes with an ED50 ofV10 pM, arrestin 3 bound with only
mM a⁄nity to the 3i loop peptide and did not promote re-
ceptor desensitization [16]. Thus, desensitization of the LH/
CG R is selectively mediated by arrestin 2 binding to the 3i
loop of the active receptor. Consistent with the absence of
detectable levels of arrestin 3 in follicular membranes, arrestin
3 did not coimmunoprecipitate with active (or inactive) LH/
CG R [16]. Thus, arrestin 3 does not participate in LH/CG R
desensitization.
An Asp residue in the 3i loop of the LH/CG R is crucial for
arrestin 2 binding [16]. Mutation of the Asp to a Gly yielded a
receptor that did not bind arrestin 2 or become desensitized
[16] and which exhibited mild constitutive activity [50^52].
Mutation of the Asp to the similarly charged Glu, to Asn
which is uncharged but has similar hydrogen bonding capa-
bility, or to non-polar Val yielded receptor that did not bind
arrestin 2 [16]. This Asp residue in the 3i loop is therefore
crucial for arrestin 2 binding to the LH/CG R. However, this
Asp residue does not simply substitute for the negatively
charged phosphate group of other GPCRs since a D564G
mutant LH/CG R expressed in HEK293 cells was not desen-
sitized by arrestin 2 mutants that are ‘constitutively active’
and do not require phospho-receptor to achieve high a⁄nity
binding to receptor [16]. The homologous Asp residue is con-
served in the glycoprotein hormone and cannabinoid recep-
tors but is generally replaced with a similarly charged Glu
residue in most other GPCRs [53]. Perhaps this conserved
Asp may also allow the other glycoprotein hormone and can-
nabinoid receptors to bind arrestin 2 in a phosphorylation-
independent manner to promote desensitization.
3.2. The GTP-dependent step of LH/CG R desensitization is
the undocking of arrestin 2
It can be readily demonstrated in a cell-free membrane
model that agonist-dependent LH/CG R desensitization crit-
ically requires GTP [37,38,40,41]. However, arrestin 2 binding
to the active LH/CG R does not constitute the GTP-depen-
dent step of LH/CG R desensitization since addition of exog-
enous arrestin 2 promotes desensitization in the absence of
GTP [48]. This result indicates that the GTP-dependent step
is upstream of arrestin 2 binding to the LH/CG R. To deter-
mine whether the GTP-dependent step of LH/CG R desensi-
tization was the release of arrestin 2 from its membrane dock-
ing site, membranes were incubated (30 min at 30‡C) without
agonist but in the presence or absence of 100 WM GTP. Mem-
branes were then washed, and pellets assayed for arrestin 2
content by Western blotting and for LH/CG R desensitization
by AC assays. GTP promoted the release of the majority of
membrane-delimited arrestin 2 from its docking site (Fig. 2A,
compare lanes 1 and 2). Moreover, these membranes were no
longer capable of agonist-dependent LH/CG R desensitization
[48], suggesting that the obligatory arrestin 2 had been washed
away. These results establish that the arrestin 2 required for
LH/CG R desensitization is not simply trapped in the mem-
branes. Rather, GTP is required to free arrestin 2 so that it is
accessible to bind to active LH/CG R.
3.3. Activation of ARF6 triggers the undocking of arrestin 2
That desensitization requires GTP in the presence of ago-
nist suggests the probable involvement of a G protein. As our
earlier studies suggested that desensitization appeared to be
independent of heterotrimeric G proteins [54], we directed our
attention to the large families of monomeric small G proteins.
Preincubation of follicular membranes with active toxins
which selectively inhibited Rho, Ras, Rap and Rac GTPases
did not a¡ect desensitization [48]. Desensitization was also
una¡ected by preincubation with brefeldin A [48], a fungal
metabolite that inhibits the guanine nucleotide exchange ac-
tivity of many GEFs that activate ARFs 1^5 but not those
like ARNO that activate ARF6 [4,55]. ARF6 was thus a
Fig. 2. The release of arrestin 2 from its membrane docking site in the absence of receptor agonist requires either high concentrations of GTP
or exogenous ARNO and low GTP concentrations. A: Ovarian follicular membranes were incubated (30 min at 30‡C, in 25 mM bis-Tris-pro-
pane bu¡er, pH 7.2, 5 mM MgCl2, 1 mM EGTA, 0.4 mM EDTA) in the absence of receptor agonist but in the presence of water, 100 WM
GTP, or 100 WM GTP plus 25 WM Non-Myr ARF6 peptide, as indicated, diluted V25-fold with 10 mM Tris^HCl, and pelleted. Pelleted mem-
branes were subjected to SDS^PAGE and Western blot analysis using anti-arrestin 2 antibody. B: Membranes were incubated as in A in the
presence of indicated additions, then diluted and subjected to SDS^PAGE and Western blot analysis. From Mukherjee et al. [48].
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candidate for the G protein required for LH/CG R desensiti-
zation. Addition of nM concentrations of ARNO, a GEF
which activates both ARF1 and ARF6, in the absence of
agonist promoted desensitization of active LH/CG R [48].
ARNO was e¡ective only in the presence and not in the ab-
sence of GTP [48]. ARNO containing a mutated PH domain
(ARNO[R280D]) or a mutation in the catalytic site (AR-
NO[E156K]) did not promote desensitization [48]. Most im-
portantly, the e¡ect of ARNO was completely reversed by
neutralizing anti-arrestin antibodies that prevent interactions
of all arrestins with GPCRs [48]. Overall, these results suggest
that ARNO promoted the apparent release of arrestin 2 from
its membrane docking site (see Fig. 1A). Critical tests yielded
results that support this model. When receptor was not acti-
vated, the addition of exogenous ARNO plus 1 WM GTP
promoted the release of arrestin 2 from its membrane docking
site which was washed away when membranes were repelleted
(Fig. 2B, compare lanes 1 and 2) [48]. When receptor was
activated, catalytically inactive ARNO blocked agonist-depen-
dent LH/CG R desensitization by preventing arrestin 2 release
from its docking site, evidenced by the retention of mem-
brane-associated arrestin 2 which was not competed away
by synthetic 3i loop peptide [56]. Taken together these results
indicate that a pool of arrestin 2 is sequestered at the plasma
membrane and that this pool can be discharged by a GTP-
dependent pathway regulated by LH/CG R activation and
ARNO.
As ARNO activates both ARF1 and ARF6, we sought to
determine whether the activation of ARF1 or ARF6 was me-
diating LH/CG R-stimulated desensitization by releasing se-
questered arrestin 2. Upon preincubation of follicular mem-
branes with synthetic N-terminal peptides of ARF1 and
ARF6 which inhibit activation of ARF1 and ARF6 [57,58],
respectively, only the ARF6 inhibitory peptide blocked arrest-
in 2 release (Fig. 2A, lane 3). The ARF6 inhibitory peptide,
but not the ARF1 inhibitory peptide, also inhibited the ability
of LH/CG R to activate ARF6 activity in follicular mem-
branes [15] and abrogated agonist-dependent desensitization
[48]. These results indicate that LH/CG R activation indeed
stimulates the activation of ARF6 and consequent release of a
pool of arrestin 2. Conversion of ARF6 from its GDP-bound
to its active GTP-bound state thus appears to comprise the
GTP-dependent step of LH/CG R desensitization.
Our model for the roles of ARNO and ARF6 in LH/CG R
desensitization is depicted in Fig. 1. ARNO, ARF6, and ar-
restin 2 are readily detected by western blotting in the AC-
enriched follicular membrane preparation [15,47,48,56]. Upon
receptor activation and consequent ARF6 activation (panel
B), a pool of arrestin 2 is released from its membrane docking
site and binds with high a⁄nity to the 3i loop of the active but
unphosphorylated receptor (panel C). We have shown that
ARNO causes LH/CG R desensitization [48], that ARNO is
present in follicular membranes at a relatively high concen-
tration (1.5 Wg or 32 nmol/mg membrane protein), and that
catalytically inactive ARNO blocks agonist-stimulated LH/
CG R desensitization [56]. We have not proven, however,
whether ARNO is the GEF responsible for ARF6 activation
downstream of LH/CG R activation by agonist or if another
GEF is responsible. Arrestin 2 binding to the receptor uncou-
ples the R from Gs, leading to a reduced rate of cAMP pro-
duction. ARF6 activation thus serves as a trigger to release
arrestin 2.
4. Does ARF6 play a restricted role in LH/CG R
desensitization or a more universal role in GPCR
desensitization and internalization?
We have recently shown that the murine LH/CG R stably
expressed in HEK293 cells also exhibits agonist-dependent
cell-free receptor desensitization [16]. This desensitization is
dependent on membrane-bound arrestin 2 and inhibited by
neutralizing anti-arrestin antibodies [16]. LH/CG R desensiti-
zation in HEK293 cells is also speci¢cally inhibited by the
inhibitory N-terminal ARF6 peptide [16]. The presence of
the agonist-dependent ARF6-regulated release of arrestin 2
from a docking site in HEK293 cell membranes (which do
not normally express LH/CG Rs) suggests that this pathway
may be a more widespread mechanism to regulate the acces-
sibility of arrestin 2 to bind to active GPCRs. Support for this
hypothesis was provided by evidence that ARF activation
occurs in response to the activation of a number of GPCRs,
including the FSH R [15], L2-AR [10], m3 muscarinic acetyl-
choline R [11], fMet-Leu-Phe R [12], H2 histamine R and B2
bradykinin R [13]. While some of these examples of GPCR-
stimulated ARF activation are believed to lead to activation
of phospholipase D [13,59,60], it is entirely possible that they
also stimulate arrestin 2 release. Support for this hypothesis
was also provided by evidence that over-expression of the
ARF GAP GIT1 inhibits L2-AR internalization [61], and by
recent evidence that over-expressed ARNO can stimulate
while GTP binding-de¢cient ARF6 retards the rate of L2-
AR internalization in HEK293 cells [62]. The relationship
between GPCR desensitization and internalization is complex,
probably receptor-speci¢c, and has not been extensively eval-
uated. For some GPCRs, the same arrestin binding to a single
site on the receptor probably leads to both desensitization and
internalization [63,64]. For other GPCRs, there is recent evi-
dence that arrestins (same or distinct?) bind to two di¡erent
regions on the receptor, one of which drives desensitization
and the other drives internalization [28]. For the latter group
of GPCRs, whether the availability of the arrestin which
drives receptor internalization is regulated by ARF6 or
more likely is recruited from the cytosol [21] has not been
clari¢ed.
5. Concluding remarks
It is our hypothesis that the GPCR-stimulated ARF6 acti-
vation which liberates a pool of arrestin 2 to bind to active
receptor may be a relatively universal mechanism to trigger
arrestin release for desensitization. Future studies are needed
to test this hypothesis. For some GPCRs, an additional re-
straint is placed on the receptor by the requirement that the
receptor be phosphorylated by a GRK in order to achieve
high a⁄nity arrestin binding. For the LH/CG R, this impedi-
ment to arrestin 2 binding is not imposed, possibly to insure
that uncoupling of the active receptor from Gs and cAMP
formation occurs and/or to insure the initiation of additional
signaling pathways as a consequence of arrestin 2-LH/CG R
interactions. It is not surprising, based on the importance of
the LH/CG R to ovulation, corpus luteum formation, and
fetal survival, that the activity of the LH/CG R to signal is
precisely regulated.
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